Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b study of IMGN151 with or without combination therapy in gynecologic cancers
jRCT2051250091Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of opugotamig olatansine in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (5 arms), sponsored by AbbVie Inc. Primary endpoints: Number of participants with dose-limiting toxicities (DLTs) and Percentage of participants with adverse events (AEs). Started Nov 2025; status: recruiting.
02
Drugs
opugotamig olatansine
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCT2051250091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250091.